What's the future of Personalised Health? LivWiSE panel discussion

LivWiSE 'What's the Future of Personalised Health?' panel discussion. CANCELLED

5:30pm - 6:45pm / Thursday 8th March 2018 / Venue: GFLEX, ground floor atrium Central Teaching Hub
Type: Lecture / Category: Department / Series: Liverpool Women in Science and Engineering
  • 0151 795 0673
  • Suitable for: LivWiSE is an open society for everyone studying, working in, or who has an interest in STEM. Members of LivWiSE range in age and experience, from students and academics to alumni and business people involved and interested in any aspect of engineering, science, technology and medicine. Membership is open to both women and men of all ages. Join LivWiSE to be kept up to date on events, activities and news. Visit our website www.liv.ac.uk/livwise, Facebook www.facebook.com/liverpoolWiSE or Twitter @LivUniWiSE
  • Admission: All welcome. Places are FREE but limited, book now Eventbrite
  • Book now
Add this event to my calendar

Create a calendar file

Click on "Create a calendar file" and your browser will download a .ics file for this event.

Microsoft Outlook: Download the file, double-click it to open it in Outlook, then click on "Save & Close" to save it to your calendar. If that doesn't work go into Outlook, click on the File tab, then on Open & Export, then Open Calendar. Select your .ics file then click on "Save & Close".

Google Calendar: download the file, then go into your calendar. On the left where it says "Other calendars" click on the arrow icon and then click on Import calendar. Click on Browse and select the .ics file, then click on Import.

Apple Calendar: The file may open automatically with an option to save it to your calendar. If not, download the file, then you can either drag it to Calendar or import the file by going to File >Import > Import and choosing the .ics file.

**UPDATE 8 MARCH 2018: Due to adverse weather conditions, this event has been cancelled**

Come along to our next "What's the Future...of personalised health?" panel discussion.

Personalised health is a new term being used to describe the future of healthcare, but what does this mean? Humans are all unique and the state of our health is influenced by many factors including genetics, lifestyle and environment. By examining and analysing our individual information, patterns can be identified to help determine our individual risk of developing disease, detect illness earlier and find the most effective interventions to help improve our health.

Our panel of experts will be discussing the medical move away from ‘one size fits all’ approach, the achievements and challenges of technological and scientific advances and the future of personalised health.

Panellists include

Dr Rachel Bearon - leads the mathematical biology research group and is responsible for User Engagement at the Liverpool Centre of Mathematics for Healthcare (LCMH). She has extensive experience of developing models bridging spatial and temporal scales to make biological predictions concerning the movement of cells within complex environments. Furthermore, she has significant expertise working directly with experimental biologists to develop novel frameworks for processing and integrating imaging data.

Rachel applies and develops mathematics to study the spatial and temporal dynamics of a wide range of biological systems across multiple scales, ranging from bacterial chemotaxis from the swimming micro-organisms phytoplankton in turbulence to modelling cell-signalling pathways and intracellular protein dynamics.



Dr Lauren Walker - an NIHR Academic Clinical Lecturer in Clinical Pharmacology & Therapeutics and general internal medicine. Her research interest is in the treatment of drug-resistant epilepsy. She qualified in medicine from the University of Liverpool, with an additional intercalated honours degree in human anatomy and cell biology.

Through her clinical lectureship Lauren continues to investigate potential biomarkers for epilepsy. She is examining patients with newly diagnosed epilepsy and whether the disulphide form of HMGB1 can predict whether or not newly-diagnosed patients with epilepsy are likely to go on to develop drug-resistance. If so, these patients could be targeted with immune-modulatory drugs. This is important as it may provide novel ways of treating patients, particularly the 30% who do not become seizure free.



Dr Andrea Jorgensen - qualified with an MSc (Distinction) in Medical Statistics at Lancaster University in 2004 (sponsored by AstraZeneca), and was awarded a PhD in Medical Statistics from the University of Liverpool in 2010. Currently a Senior Lecturer in Biostatistics at the University of Liverpool, specialising in statistical methods for pharmacogenetics and stratified medicine.

Dr Jorgensen's main research interests include statistical methods for pharmcogenetic studies and stratified medicine, randomised controlled trials in stratified medicine, meta-analysis of pharmacogenetics studies, and methodological quality of pharmacogenetic studies.